India produces over 1/5th of bulk drug production in the world. However, the bulk drugs manufacturers are facing regulatory hurdles in many area. Currently, irrespective of pollution load, change in product mix have to be notified with Ministry of Environment and has to be approved by them. There are many cases, where there may be drop in pollution load because of change in product mix, but the company has to spend over 6 months to get approval. Besides, the effluent treated out of the company has to be mandatoriy treated again in Common Effluent Treatment plants of same standard. This increases cost and capital expenditure. In global export scenario, Chinese are proactive to tweak regulation to suit their interest, while India takes more time. No wonder, we import more than 60% of our bu
Enal Drugs is planning an expansion programme of its plant in Wangapally in Yadagirigutta in Nalagonda district of Telangana. The project involves expanding manufacturing capacity of active pharmaceutical ingredients from 966 tpa to 1800 tpa. The project cost is estimated at Rs. 400 million. After expansion, the plant will produce Lansoprazole, Rabeprazole Sodium, Zalepon, Omeprazole and other anti ulcerative drug intermediates.
Telangana government is ready to unveil a draft new policy on Pharma and Bulk Drug Sector. The state government has acquired 11,000 acres of land at Mucherla at the outskirts of Hyderabad . (roughly 70 kms away ) They are in the process of preparing a detailed project report (DPR) in coordination with the pharma industry and the pollution control board so that every ingredient required for the industry and environment safety is incorporated.
With the ?Make in India policy? of the government, the industry is expecting sops like tax breaks, weighted tax deduction at 150 per cent for R&D expenditure and availability of affordable land for the industry.
Already, Hyderabad has a strong base for bulk drug industries in India contributing one third of country?s bulk drug production. Taking t